The MRNA vaccine developed by China National Medicine Group for the MRN of the Omircong mutation, on Thursday (January 19), has officially obtained the clinical trial approval of the China National Drug Administration.
According to the "China Biological" WeChat public account, Zhang Yuntao, the vice president of Chinese Biopsy, the vice president of Chinese biological biological biological, said thatThe innovative MRNA vaccine of the Rongyee's full -length S protein is an important result of the R & D and production platform of the MRNA vaccine after the technical route of Chinese organisms and reorganization vaccines.
Zhang Yuntao said that the technical research and development of this vaccine has been benchmarked from all aspects from the beginning of the project, and it will accelerate clinical trials.
Jiao Weiguo, chief scientist of Zhongsheng Fujian Jian, introduced that this vaccine uses a new type of antigen design, which further improves the ability to induce effective neutralization and antibody.Attacking protection effect.Vaccination is the leading global technology, and advanced MRNA-LNP packaging technology can further ensure production capacity.
Zhongsheng Fujian has built a trial research and development platform from Shanghai Nanxiang's MRNA vaccine drugs, and an intelligent MRNA vaccine workshop with an annual production capacity of 2 billion doses.Next, Zhongsheng Fu Nuojian will promote the clinical trial of the Omikon MRNA vaccine, and adopts the form of random, double -blindness, and placebo parallel control.Play.
